RECURRENT MYELODYSPLASTIC SYNDROME
Clinical trials for RECURRENT MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for RECURRENT MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug TAK-243 targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study is testing a drug called TAK-243 in people whose acute myeloid leukemia or myelodysplastic syndrome has come back or is not responding to treatment. The goal is to find the best dose and check for side effects. The trial is currently on hold.
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New drug combo targets tough blood cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called cirtuvivint, alone or with another drug combo (ASTX727), in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The goal is to find the safest dose and check for side effects. About 54 participants whose…
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for blood cancer patients: canakinumab trial targets Low-Risk MDS and CMML
Disease control Recruiting nowThis study tests a drug called canakinumab in people with low- or intermediate-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The drug is a lab-made antibody that may help slow cancer growth and improve blood cell counts. About 76 adults will rece…
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Supercharged immune cells take on relapsed leukemia
Disease control Recruiting nowThis early-phase trial tests a new immunotherapy for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered donor T cells designed to recognize and attack a protein called HA-1 found …
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo attack on tough blood cancers: chemo plus transplant shows promise
Disease control Recruiting nowThis study tests a new approach for adults with aggressive blood cancers (like AML) that are likely to return after standard treatment. Participants receive a combination of chemotherapy drugs (decitabine plus FLAG-Ida) and low-dose radiation, followed immediately by a stem cell …
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo attack on stubborn leukemia: chemo then transplant
Disease control Recruiting nowThis early-phase trial tests a two-step approach for people with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. First, patients receive intensive chemotherapy (CLAG-M or FLAG-Ida) followed immediately by a reduced-intensity stem …
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could detoxing metals boost chemo for leukemia?
Disease control Recruiting nowThis early-stage trial is testing whether two drugs that lower metal levels in the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. The study will enroll 58 adults and aims to find the safest dose and check f…
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New pill Q702 aims to outsmart blood cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called Q702 in people with various blood cancers and related disorders that have not responded to standard treatments. Q702 is designed to help the immune system attack cancer cells and help the bone marrow make healthy blood cells. Th…
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC